Web Exclusive. Annals On Call - COVID-19: Is Chloroquine the Answer?

Abstract

Web Exclusives5 May 2020Annals On Call - COVID-19: Is Chloroquine the Answer?FREERobert M. Centor, MD, Alfred Hyoungju Kim, MD, PhD, and Jeffrey A. Sparks, MD, MMScRobert M. Centor, MDHuntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Search for more papers by this author, Alfred Hyoungju Kim, MD, PhDWashington University School of Medicine, St. Louis, Missouri (A.H.K.)Search for more papers by this author, and Jeffrey A. Sparks, MD, MMScBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (J.A.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/A20-0003 CME/MOC SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In this episode of Annals On Call, Dr. Centor discusses the evidence that generated interest in the potential role of hydroxychloroquine in the treatment of COVID-19. Annals articles discussed include...A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19: https://annals.org/aim/fullarticle/2764065/rush-judgment-rapid-reporting-dissemination-results-its-consequences-regarding-useUse of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know: https://annals.org/aim/fullarticle/2764199/use-hydroxychloroquine-chloroquine-during-covid-19-pandemic-what-every-clinicianAbout Annals On CallAnnals On Call focuses on a clinically influential article published in Annals of Internal Medicine. Dr. Robert Centor shares his own perspective on the material and interviews topic area experts to discuss, debate, and share diverse insights about patient care and health care delivery.For more information on Annals On Call and for more episodes, visit go.annals.org/OnCall. Comments0 CommentsSign In to Submit A Comment Dr Muhammad FarooqPhysician Internest & Rheumatologist18 April 2020 Well Explained Nicely explained & well summarised the outcomes of the current Trials on HCQ use as a Potential treatment & as a prophylaxis. Disclosures: No Author, Article, and Disclosure InformationAffiliations: Huntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Washington University School of Medicine, St. Louis, Missouri (A.H.K.)Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (J.A.S.)Disclosures: Dr. Centor has disclosed the following: Consultancy: DynaMed, MDCalc, Medscape, National Kidney Foundation, The Curbsiders. Employment: U.S. Department of Veterans Affairs. Dr. Kim has disclosed the following: Research grants/contracts: GlaxoSmithKline. Consultantship and speakers bureau: Exagen Diagnostics, GlaxoSmithKline. Dr. Sparks has disclosed the following: Research grants/contracts: National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Allergy and Infectious Diseases, Autoimmune Centers of Excellence, Rheumatology Research Foundation, Brigham Research Institute, the R. Bruce and Joan M. Mickey Research Scholar Fund. Consultantship: Bristol-Myers Squibb, Gilead, Inova, Janssen, Optum.Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Darren B. Taichman, MD, PhD, Executive Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Eliseo Guallar, MD, MPH, DrPH, Deputy Editor, Statistics, reports that he has no financial relationships or interests to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Christina C. Wee, MD, MPH, Deputy Editor, reports employment with Beth Israel Deaconess Medical Center. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Yu-Xiao Yang, MD, MSCE, Deputy Editor, reports that he has no financial relationships or interest to disclose.This article was published at Annals.org on 9 April 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUse of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know Jinoos Yazdany and Alfred H.J. Kim A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19 Alfred H.J. Kim , Jeffrey A. Sparks , Jean W. Liew , Michael S. Putman , Francis Berenbaum , Alí Duarte-García , Elizabeth R. Graef , Peter Korsten , Sebastian E. Sattui , Emily Sirotich , Manuel F. Ugarte-Gil , Kate Webb , Rebecca Grainger , and Metrics Cited byRisk perception, public health interventions, and Covid-19 pandemic control in sub-saharan AfricaCOVID-19 Pandemic: Can Maintaining Optimal Zinc Balance Enhance Host Resistance? 5 May 2020Volume 172, Issue 9Page: OC1KeywordsCOVID-19ChloroquineDiagnostic techniquesDisclosureHydroxychloroquineMuscular dystrophiesResearch fundingResearch grantsRheumatologySkin diseases ePublished: 9 April 2020 Issue Published: 5 May 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.Loading ...